	US 11,939,372 B2
	Binding agents
Christopher J. Paszty, Ventura, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Oct. 23, 2019, as Appl. No. 16/661,669.
Application 15/043,925 is a division of application No. 13/691,344, filed on Nov. 30, 2012, granted, now 9,296,812.
Application 13/691,344 is a division of application No. 12/950,094, filed on Nov. 19, 2010, granted, now 8,383,801.
Application 12/950,094 is a division of application No. 12/276,889, filed on Nov. 24, 2008, granted, now 7,872,106.
Application 12/276,889 is a division of application No. 11/411,003, filed on Apr. 25, 2006, granted, now 7,592,429.
Application 16/661,669 is a continuation of application No. 15/043,925, filed on Feb. 15, 2016, granted, now 10,562,964.
Claims priority of provisional application 60/792,645, filed on Apr. 17, 2006.
Claims priority of provisional application 60/782,244, filed on Mar. 13, 2006.
Claims priority of provisional application 60/776,847, filed on Feb. 24, 2006.
Claims priority of provisional application 60/677,583, filed on May 3, 2005.
Prior Publication US 2020/0048338 A1, Feb. 13, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01); C07K 14/51 (2006.01); C07K 14/76 (2006.01); C07K 14/79 (2006.01); C07K 16/18 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/22 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); C07K 14/51 (2013.01); C07K 14/76 (2013.01); C07K 14/79 (2013.01); C07K 16/18 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)]

10 Claims

1. A method of isolating an antibody that binds sclerostin of SEQ ID NO: 1, the method comprising (a) performing a cross-blocking assay with (i) a first antibody and (ii) a second antibody comprising heavy chains of SEQ ID NO: 209 and light chains of SEQ ID NO: 205 in the presence of sclerostin of SEQ ID NO: 1, and (b) isolating a first antibody that competes with the second antibody for binding to sclerostin.